Vera Therapeutics Wins FDA Accelerated Approval For TRUTAKNA In Primary IgA Nephropathy
(RTTNews) – Vera Therapeutics, (VERA), a commercial-stage biotechnology company, announced that the U.S. Food and Drug Administration (FDA) granted TRUTAKNA (atacicept-vymj) accelerated approval to reduce proteinuria in adults with primary IgA nephropathy or IgAN at risk for disease progression. IgA Nephropathy is a serious, progressive, immune-mediated kidney disease and a leading cause of chronic kidney […]